LakePharma’s biorepository facility is part of its good manufacturing practice (GMP) microbiomanufacturing center in the Boston area. The center began operations last month and is now producing GMP-grade plasmid DNA.
A spokesperson for LakePharma, a contract research, development, and manufacturing organization (CRDMO) told us, “Since LakePharma has already established four other facilities focusing on upstream discovery and development, the next logical step is to establish a GMP facility–LakePharma’s microbiomanufacturing Center—dedicated to GMP manufacturing.”
The biorepository facility has the capabilities to store drug developers’ materials in the required temperature conditions.
LakePharma’s CEO, Hua Tu, said in a statement that the biorepository aligns itself with the company’s manufacturing services and capabilities. The biorepository extends the company’s ability to offer an end-to-end client solution, providing a “one-stop” solution from manufacturing to long term storage of biological materials, he said
“The market demand for cGMP services continues to expand, and LakePharma expects to participate in that growth. We will scale our manufacturing capabilities and plan on hiring an additional 50 staff this year," added Tu.
